Skip to content
IPOandMore
  • Home
  • IPO/OFS/Stocks
    • IPO Review
    • Post IPO Analysis
    • Stock Analysis
  • Buybacks / Spl Situations
    • Recent Buybacks (Last 50)
    • All BuyBacks
    • Buyback Review
    • Special Situations
  • NCDs / Fixed Income
    • Fixed Income
    • NCD ReviewNCD Analysis & Review
  • Mutual Funds
  • Personal Finance
  • NRI
  • About
  • Toggle website search
Menu Close
  • Home
  • IPO/OFS/Stocks
    • IPO Review
    • Post IPO Analysis
    • Stock Analysis
  • Buybacks / Spl Situations
    • Recent Buybacks (Last 50)
    • All BuyBacks
    • Buyback Review
    • Special Situations
  • NCDs / Fixed Income
    • Fixed Income
    • NCD Review
  • Mutual Funds
  • Personal Finance
  • NRI
  • About
  • Toggle website search

Mankind Pharma IPO

  1. Home>
  2. Mankind Pharma IPO

Mankind Pharma IPO Review

  • Post author:[email protected]
  • Post published:April 26, 2023
  • Post category:IPO Review
  • Post comments:0 Comments

Mankind Pharma’s IPO is entirely an offer for sale (OFS) of 40,058,844 equity shares by promoters and other existing shareholders to raise around Rs. 4,326 cr. The offer for sales…

Continue ReadingMankind Pharma IPO Review

Archives

Categories

Copyright - WordPress Theme by OceanWP